NEW
YORK, Aug. 24, 2022 /PRNewswire/ -- GLO Pharma,
the parent company of breakthrough subtopical skincare brand
Ourself, today announces the appointment of Brent Saunders to its Board of Directors. Mr.
Saunders, who currently serves as Executive Chairman of The Beauty
Health Company, will join the board effective immediately. His
appointment adds a new seat to the GLO Pharma board, which now
consists of six members and is led by Chairman Scott L. Glenn.
Mr. Saunders is a respected innovator who brings to the Board
his extensive leadership experience in the biopharma and medical
aesthetics sectors, having led several mergers and acquisitions and
served as multiple leadership roles at prominent global
pharmaceutical and healthcare companies.
From July 2020 to May 2021, Mr. Sauders served as President, Chief
Executive Officer and Chair of the Board of Directors of Vesper
Healthcare Acquisition Corp. ("Vesper"), and led Vesper's merger
with The HydraFacial Company to become The Beauty Health Company,
of which he continues to serve as Executive Chair. Prior, he served
as CEO and President of Allergan plc ("Allergan"), best known as
the maker of Botox, from July 2014 to
May 2020, and was instrumental in
leading Allergan's acquisition by AbbVie, Inc. He also served on
Allergan's board July 2014 to
May 2020, and as its Chair from
October 2016 to May 2020.
Mr. Saunders previously served as Chief Executive Officer and
President of Forest Laboratories, Inc. ("Forest"), and later as CEO
of pharmaceutical company Actavis, after that company acquired
Forest. Later, Saunders negotiated Actavis' merger with Allergan,
which closed at $70.5 billion. Mr.
Saunders also held the role of Chief Executive Officer of Bausch +
Lomb Incorporated, a leading global eye health company, where he
oversaw the company's acquisition by Valeant Pharmaceuticals in
2013. From 2003 to 2010, he held numerous leadership positions at
Schering-Plough Corporation, where he led the company's merger with
Merck & Co. and its acquisition of Organon BioSciences. He is
the founder of the SPAC Vesper Healthcare Acquisition, and also
currently serves on the boards of directors of BridgeBio Pharma,
Inc. and Cisco (NASDAQ: CSCO).
"Mr. Saunders' experience with scaling and transforming
biopharma and medical aesthetics businesses, first with Allergan
and now with The Beauty Health Company, makes him an invaluable
asset to the GLO Pharma Board," says Chairman Scott Glenn. "As we build out the product
offering of our consumer brand Ourself and a roadmap of topical
alternatives to medical procedures, Brent brings incredible insight
to the conversation, especially as we develop new innovation in the
wrinkle relaxer category in the near future."
This appointment follows the recent announcement of Rothy's CFO
Dayna Quanbeck to the GLO Pharma
Board, and launch of GLO Pharma's first consumer brand, Ourself, in
February 2022. Ourself is backed by
$40M in funding to date from
investors including Lightspeed Venture Partners, First Round
Capital, and Mr. Glenn.
Media Contact:
Factory PR // Liz Hill
liz@factorypr.com
About GLO Pharma:
GLO Pharma is a biotechnology company dedicated to developing
innovative approaches to beauty and aesthetics. It was founded in
2018 by Scott Glenn and Lauren
Otsuki, innovators within the biotechnology space for over 20
years. Mr. Glenn and Ms. Otsuki previously founded and developed
professional skincare companies Alastin Skincare and SkinMedica,
along with numerous pharmaceutical companies aimed at solving some
of the toughest medical issues in infertility, diabetes,
cardiovascular disease, and cancer. In 2022, GLO Pharma launched
its first consumer brand, Ourself, as the first-ever Subtopical
Skincare System™, bridging the gap between traditional skincare
products and clinical procedures through the use of
biotechnology.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/glo-pharma-appoints-current-executive-chairman-of-the-beauty-health-company-and-former-allergan-plc-ceo-brent-saunders-to-its-board-of-directors-301611368.html
SOURCE GLO Pharma